ACULAR LS Rx
Generic Name and Formulations:
Ketorolac tromethamine 0.4%; oph soln; contains benzalkonium chloride.
Indications for ACULAR LS:
Ocular pain and burning/stinging after corneal refractive surgery.
Adults and Children:
<3yrs: not established. ≥3yrs: 1 drop 4 times daily as needed for up to 4 days post-op.
Do not administer while wearing contacts. Bleeding tendencies. Complicated or repeat ocular surgeries. Corneal defects/denervation. Ocular surface diseases. Diabetes. Rheumatoid arthritis. May delay wound healing. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Hypersensitivity to aspirin. History of asthma. Pregnancy (Cat.C): avoid in late pregnancy. Nursing mothers.
May potentiate oral anticoagulants.
Transient stinging, burning, conjunctival hyperemia, corneal infiltrates, headache, ocular edema, ocular pain/inflammation/irritation, superficial keratitis or infections, allergic reactions, increased ocular bleeding (including hyphemas).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|